Drugs / Coagadex
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Coagadex | — | 2016-03-16 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06963216 | Jun 2026 | acquired factor X deficiency | Kedrion S.p.A. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coagadex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963216 ↗ |
| Known as | Coagadex(R) | “Biological: Coagadex(R)” NCT06963216 ↗ |
| Modality | Protein / enzyme biologic | “Coagadex® is a plasma-derived human coagulation factor concentrate expected to treat bleeding episodes” NCT06963216 ↗ |